August 15, 2026 08:04 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe | From guns to glamour: Former women Maoists walk the ramp in Chhattisgarh | Netaji row: Suvendu Adhikari govt strips BJP MP Anant Maharaj of state honour | Sukhbir Badal attacked by Nihang Sikh with kirpan at Maharashtra gurdwara; assailant detained | ‘If you cannot do it, we will pass an order’: Supreme Court’s final warning to Centre on food labels | ‘Time to move on’: Bombay HC sends strong message in Vijay Mallya-bank dispute

Philippines healthcare providers administer vaccine approved for prevention of Dengue

| | Feb 23, 2016, at 05:00 am
Kolkata/Lyon, Feb 22 (IBNS): Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday that vaccinations with Dengvaxia have commenced in the Philippines following official receipt of the first shipment of the vaccine earlier this month.
Dengvaxia, a tetravalent dengue vaccine, was approved in the Philippines on 22 December 2015 for the prevention of disease caused by all four Dengue types in individuals from 9-45 years of age living in endemic areas. 
 
The vaccine is administered in three doses given over a one-year period. Asia bears 70% of dengue fever burden globally with an estimated 67 million people being sickened by the disease annually. 
 
In the Philippines alone, over 110,000 people on average get Dengue every year. Asian endemic countries spend an estimated 6.5 billion USD annually in both direct medical and indirect costs due to Dengue.
 
“This is truly a great moment in the history of vaccinology,” states Guillaume Leroy, Vice-President of Dengue Vaccine, Sanofi Pasteur. “Dengvaxia’s availability for administration by healthcare providers in the Philippines, to be followed closely by the initiation of a public sector immunization program in the country is a landmark event for global Dengue prevention and a great achievement for the people of the Philippines.”
 
Medical Societies in the Philippines held a media event in Manila earlier this month to welcome receipt of the first shipment of Dengvaxia to the country.
 
In attendance, Dr. Rose Capeding, chief of the Research Institute for Tropical Medicine’s department of microbiology, noted that the Philippines participated in all three phases of the clinical development of the vaccine and that healthcare providers there were delighted to be able to begin vaccinating against dengue, which continues to pose a major public health threat to the nation.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.